Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORUM2 platform for HSCT management in pediatric acute lymphoblastic leukemia
2025-522052-13-00Phase 3Authorised
- Sponsor
- Ospedale Pediatrico Bambino Gesù
- Start
- Dec 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of blinatumomab, ruxolitinib, thiotepa, fludarabine, busulfan and 6 more in acute lymphoblastic leukemia (ALL) (6 arms), sponsored by Ospedale Pediatrico Bambino Gesù. Primary endpoints: Event-free survival at 4 years, Overall response rate at Day 28 and 2 more. Planned start Dec 2025; status: authorised.
02
Drugs
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2025-522052-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522052-13-00.